Patent Foramen Ovale, the Role of Antiplatelet Therapy Alone or Anticoagulant Therapy Alone Versus Device Closure for Cryptogenic Stroke: A Review of the Literature and Current Recommendations

Author(s): Harsha S. Nagarajarao*, Chandra P. Ojha, Archana Kedar, Debabrata Mukherjee

Journal Name: Cardiovascular & Hematological Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents

Volume 18 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Cryptogenic stroke and its relation to the Patent Foramen Ovale (PFO) is a long-debated topic. Recent clinical trials have unequivocally established the relationship between cryptogenic strokes and paradoxical embolism across the PFO. This slit-like communication exists in everyone before birth, but most often closes shortly after birth. PFO may persist as a narrow channel of communication between the right and left atria in approximately 25-27% of adults.

In this review, we examine the clinical relevance of the PFO with analysis of the latest trials evaluating catheter-based closure of PFO’s for cryptogenic stroke. We also review the current evidence examining the use of antiplatelet medications versus anticoagulants for stroke prevention in those patients with PFO who do not qualify for closure per current guidelines.

Keywords: Anticoagulation, antiplatelet therapy, cryptogenic stroke, patent foramen ovale, trans-catheter closure, stroke prevention.

[1]
Hagen, P.T.; Scholz, D.G.; Edwards, W.D. Incidence and size of patent foramen ovale during the first 10 decades of life: An autopsy study of 965 normal hearts. Mayo Clin. Proc., 1984, 59(1), 17-20.
[http://dx.doi.org/10.1016/S0025-6196(12)60336-X] [PMID: 6694427]
[2]
Lechat, P.; Mas, J.L.; Lascault, G.; Loron, P.; Theard, M.; Klimczac, M.; Drobinski, G.; Thomas, D.; Grosgogeat, Y. Prevalence of patent foramen ovale in patients with stroke. N. Engl. J. Med., 1988, 318(18), 1148-1152.
[http://dx.doi.org/10.1056/NEJM198805053181802] [PMID: 3362165]
[3]
Homma, S.; Sacco, R.L.; Di Tullio, M.R.; Sciacca, R.R.; Mohr, J.P. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation, 2002, 105(22), 2625-2631.
[http://dx.doi.org/10.1161/01.CIR.0000017498.88393.44] [PMID: 12045168]
[4]
Webster, M.W.; Chancellor, A.M.; Smith, H.J.; Swift, D.L.; Sharpe, D.N.; Bass, N.M.; Glasgow, G.L. Patent foramen ovale in young stroke patients. Lancet, 1988, 2(8601), 11-12.
[http://dx.doi.org/10.1016/S0140-6736(88)92944-3] [PMID: 2898621]
[5]
Cabanes, L.; Mas, J.L.; Cohen, A.; Amarenco, P.; Cabanes, P.A.; Oubary, P.; Chedru, F.; Guérin, F.; Bousser, M.G.; de Recondo, J. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke, 1993, 24(12), 1865-1873.
[http://dx.doi.org/10.1161/01.STR.24.12.1865] [PMID: 8248969]
[6]
Ranoux, D.; Cohen, A.; Cabanes, L.; Amarenco, P.; Bousser, M.G.; Mas, J.L. Patent foramen ovale: is stroke due to paradoxical embolism? Stroke, 1993, 24(1), 31-34.
[http://dx.doi.org/10.1161/01.STR.24.1.31] [PMID: 8418547]
[7]
Anzola, G.P.; Magoni, M.; Guindani, M.; Rozzini, L.; Dalla Volta, G. Potential source of cerebral embolism in migraine with aura: A transcranial Doppler study. Neurology, 1999, 52(8), 1622-1625.
[http://dx.doi.org/10.1212/WNL.52.8.1622] [PMID: 10331688]
[8]
Sztajzel, R.; Genoud, D.; Roth, S.; Mermillod, B.; Le Floch-Rohr, J. Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke. Cerebrovasc. Dis., 2002, 13(2), 102-106.
[http://dx.doi.org/10.1159/000047758] [PMID: 11867883]
[9]
Caputi, L.; Usai, S.; Carriero, M.R.; Grazzi, L.; D’Amico, D.; Falcone, C.; Anzola, G.P.; Del Sette, M.; Parati, E.; Bussone, G. Microembolic air load during contrast-transcranial Doppler: A trigger for migraine with aura? Headache, 2010, 50(8), 1320-1327.
[http://dx.doi.org/10.1111/j.1526-4610.2010.01621.x] [PMID: 20132338]
[10]
Wilmshurst, P. Decompression sickness. J. R. Soc. Health, 1988, 108(4), 152.
[http://dx.doi.org/10.1177/146642408810800417] [PMID: 3143007]
[11]
Wilmshurst, P.T.; Nightingale, S.; Walsh, K.P.; Morrison, W.L. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet, 2000, 356(9242), 1648-1651.
[http://dx.doi.org/10.1016/S0140-6736(00)03160-3] [PMID: 11089825]
[12]
Wilmshurst, P. Medical aspects of scuba diving. Decompression sickness may be due to paradoxical embolism. BMJ, 1994, 309(6950), 340.
[PMID: 8086885]
[13]
Wilmshurst, P.T.; Byrne, J.C.; Webb-Peploe, M.M. Neurological decompression sickness. Lancet, 1989, 1(8640), 731.
[http://dx.doi.org/10.1016/S0140-6736(89)92251-4] [PMID: 2564546]
[14]
Wilmshurst, P.T.; Byrne, J.C.; Webb-Peploe, M.M. Relation between interatrial shunts and decompression sickness in divers. Lancet, 1989, 2(8675), 1302-1306.
[http://dx.doi.org/10.1016/S0140-6736(89)91911-9] [PMID: 2574256]
[15]
Wilmshurst, P. Right-to-left shunt and neurological decompression sickness in divers. Lancet, 1990, 336(8722), 1071-1072.
[http://dx.doi.org/10.1016/0140-6736(90)92546-T] [PMID: 1977048]
[16]
Choong, C. K.; Calvert, P. A.; Falter, F.; Mathur, R.; Appleton, D.; Wells, F. C.; Schofield, P. M.; Crawford, R. Life-threatening impending paradoxical embolus caught “red-handed”: Successful management by multidisciplinary team approach. J. Thorac. Cardiovasc. Surg., , 2008, 136(2), 527-528 e8 .
[http://dx.doi.org/10.1016/j.jtcvs.2007.10.090]
[17]
Kim, R.J.; Girardi, L.N. Lots of clots: Multiple thromboemboli including a huge paradoxical embolus in a 29-year old man. Int. J. Cardiol., 2008, 129(2), e50-e52.
[http://dx.doi.org/10.1016/j.ijcard.2007.06.116] [PMID: 17869355]
[18]
Madani, H.; Ransom, P.A. Paradoxical embolus illustrating speed of action of recombinant tissue plasminogen activator in massive pulmonary embolism. Emerg. Med. J., 2007, 24(6), 441.
[http://dx.doi.org/10.1136/emj.2006.045104] [PMID: 17513552]
[19]
Dowson, A.; Mullen, M.J.; Peatfield, R.; Muir, K.; Khan, A.A.; Wells, C.; Lipscombe, S.L.; Rees, T.; De Giovanni, J.V.; Morrison, W.L.; Hildick-Smith, D.; Elrington, G.; Hillis, W.S.; Malik, I.S.; Rickards, A. Migraine intervention with STARFlex technology (MIST) trial: A prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation, 2008, 117(11), 1397-1404.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.727271] [PMID: 18316488]
[20]
Shanoudy, H.; Soliman, A.; Raggi, P.; Liu, J.W.; Russell, D.C.; Jarmukli, N.F. Prevalence of patent foramen ovale and its contribution to hypoxemia in patients with obstructive sleep apnea. Chest, 1998, 113(1), 91-96.
[http://dx.doi.org/10.1378/chest.113.1.91] [PMID: 9440574]
[21]
Mas, J.L.; Derumeaux, G.; Guillon, B.; Massardier, E.; Hosseini, H.; Mechtouff, L.; Arquizan, C.; Béjot, Y.; Vuillier, F.; Detante, O.; Guidoux, C.; Canaple, S.; Vaduva, C.; Dequatre-Ponchelle, N.; Sibon, I.; Garnier, P.; Ferrier, A.; Timsit, S.; Robinet-Borgomano, E.; Sablot, D.; Lacour, J.C.; Zuber, M.; Favrole, P.; Pinel, J.F.; Apoil, M.; Reiner, P.; Lefebvre, C.; Guérin, P.; Piot, C.; Rossi, R.; Dubois-Randé, J.L.; Eicher, J.C.; Meneveau, N.; Lusson, J.R.; Bertrand, B.; Schleich, J.M.; Godart, F.; Thambo, J.B.; Leborgne, L.; Michel, P.; Pierard, L.; Turc, G.; Barthelet, M.; Charles-Nelson, A.; Weimar, C.; Moulin, T.; Juliard, J.M.; Chatellier, G.; Investigators, C. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N. Engl. J. Med., 2017, 377(11), 1011-1021.
[http://dx.doi.org/10.1056/NEJMoa1705915] [PMID: 28902593]
[22]
Saver, J.L.; Carroll, J.D.; Thaler, D.E.; Smalling, R.W.; MacDonald, L.A.; Marks, D.S.; Tirschwell, D.L.; Investigators, R. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N. Engl. J. Med., 2017, 377(11), 1022-1032.
[http://dx.doi.org/10.1056/NEJMoa1610057] [PMID: 28902590]
[23]
Søndergaard, L.; Kasner, S.E.; Rhodes, J.F.; Andersen, G.; Iversen, H.K.; Nielsen-Kudsk, J.E.; Settergren, M.; Sjöstrand, C.; Roine, R.O.; Hildick-Smith, D.; Spence, J.D.; Thomassen, L.; Gore, R.C.S.I. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N. Engl. J. Med., 2017, 377(11), 1033-1042.
[http://dx.doi.org/10.1056/NEJMoa1707404] [PMID: 28902580]
[24]
Lee, P.H.; Song, J.K.; Kim, J.S.; Heo, R.; Lee, S.; Kim, D.H.; Song, J.M.; Kang, D.H.; Kwon, S.U.; Kang, D.W.; Lee, D.; Kwon, H.S.; Yun, S.C.; Sun, B.J.; Park, J.H.; Lee, J.H.; Jeong, H.S.; Song, H.J.; Kim, J.; Park, S.J. Cryptogenic stroke and high-risk patent foramen ovale: The DEFENSE-PFO trial. J. Am. Coll. Cardiol., 2018, 71(20), 2335-2342.
[http://dx.doi.org/10.1016/j.jacc.2018.02.046] [PMID: 29544871]
[25]
Kuijpers, T.; Spencer, F.A.; Siemieniuk, R.A.C.; Vandvik, P.O.; Otto, C.M.; Lytvyn, L.; Mir, H.; Jin, A.Y.; Manja, V.; Karthikeyan, G.; Hoendermis, E.; Martin, J.; Carballo, S.; O’Donnell, M.; Vartdal, T.; Baxter, C.; Patrick-Lake, B.; Scott, J.; Agoritsas, T.; Guyatt, G. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ, 2018, 362, k2515.
[http://dx.doi.org/10.1136/bmj.k2515] [PMID: 30045912]
[26]
Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc. Dis., 2008, 25(5), 457-507.
[http://dx.doi.org/10.1159/000131083] [PMID: 18477843]
[27]
Messé, S.R.; Gronseth, G.; Kent, D.M.; Kizer, J.R.; Homma, S.; Rosterman, L.; Kasner, S.E. Practice advisory: Recurrent stroke with patent foramen ovale (update of practice parameter): Report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Neurology, 2016, 87(8), 815-821.
[http://dx.doi.org/10.1212/WNL.0000000000002961] [PMID: 27466464]
[28]
Bridges, N.D.; Hellenbrand, W.; Latson, L.; Filiano, J.; Newburger, J.W.; Lock, J.E. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation, 1992, 86(6), 1902-1908.
[http://dx.doi.org/10.1161/01.CIR.86.6.1902] [PMID: 1451261]
[29]
Abaci, A.; Unlu, S.; Alsancak, Y.; Kaya, U.; Sezenoz, B. Short and long term complications of device closure of atrial septal defect and patent foramen ovale: Meta-analysis of 28,142 patients from 203 studies. Catheter. Cardiovasc. Interv., 2013, 82(7), 1123-1138.
[http://dx.doi.org/10.1002/ccd.24875] [PMID: 23412921]
[30]
Furlan, A.J.; Reisman, M.; Massaro, J.; Mauri, L.; Adams, H.; Albers, G.W.; Felberg, R.; Herrmann, H.; Kar, S.; Landzberg, M.; Raizner, A.; Wechsler, L.; Investigators, C.I. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N. Engl. J. Med., 2012, 366(11), 991-999.
[http://dx.doi.org/10.1056/NEJMoa1009639] [PMID: 22417252]
[31]
Morandi, E.; Anzola, G.P.; Angeli, S.; Melzi, G.; Onorato, E. Transcatheter closure of patent foramen ovale: A new migraine treatment? J. Interv. Cardiol., 2003, 16(1), 39-42.
[http://dx.doi.org/10.1046/j.1540-8183.2003.08001.x] [PMID: 12664816]
[32]
Calvert, P.A.; Rana, B.S.; Kydd, A.C.; Shapiro, L.M. Patent foramen ovale: Anatomy, outcomes, and closure. Nat. Rev. Cardiol., 2011, 8(3), 148-160.
[http://dx.doi.org/10.1038/nrcardio.2010.224] [PMID: 21283148]
[33]
Rana, B.S.; Shapiro, L.M.; McCarthy, K.P.; Ho, S.Y. Three dimensional imaging of the atrial septum and patent foramen ovale anatomy: defining the morphological phenotypes of patent foramen ovale. Eur. J. Echocardiogr., 2010, 11(10), i19-i25.
[http://dx.doi.org/10.1093/ejechocard/jeq122] [PMID: 21078835]
[34]
Schneider, B.; Hofmann, T.; Justen, M.H.; Meinertz, T. Chiari’s network: normal anatomic variant or risk factor for arterial embolic events? J. Am. Coll. Cardiol., 1995, 26(1), 203-210.
[http://dx.doi.org/10.1016/0735-1097(95)00144-O] [PMID: 7797753]
[35]
Steiner, M.M.; Di Tullio, M.R.; Rundek, T.; Gan, R.; Chen, X.; Liguori, C.; Brainin, M.; Homma, S.; Sacco, R.L. Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke, 1998, 29(5), 944-948.
[http://dx.doi.org/10.1161/01.STR.29.5.944] [PMID: 9596240]
[36]
Mojadidi, M.K.; Bogush, N.; Caceres, J.D.; Msaouel, P.; Tobis, J.M. Diagnostic accuracy of transesophageal echocardiogram for the detection of patent foramen ovale: A meta-analysis. Echocardiography, 2014, 31(6), 752-758.
[http://dx.doi.org/10.1111/echo.12462] [PMID: 24372693]
[37]
Mahmoud, A.N.; Elgendy, I.Y.; Agarwal, N.; Tobis, J.M.; Mojadidi, M.K. Identification and quantification of patent foramen ovale mediated shunts: Echocardiography and transcranial Doppler. Interv. Cardiol. Clin., 2017, 6(4), 495-504.
[PMID: 28886841]
[38]
Mojadidi, M.K.; Mahmoud, A.N.; Elgendy, I.Y.; Agarwal, N.; Tobis, J.M. Transesophageal echocardiography for the detection of patent foramen ovale. J. Am. Soc. Echocardiogr., 2017, 30(9), 933-934.
[http://dx.doi.org/10.1016/j.echo.2017.05.006] [PMID: 28602207]
[39]
Pearson, A.C.; Labovitz, A.J.; Tatineni, S.; Gomez, C.R. Superiority of transesophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology. J. Am. Coll. Cardiol., 1991, 17(1), 66-72.
[http://dx.doi.org/10.1016/0735-1097(91)90705-E] [PMID: 1987242]
[40]
Lee, R.J.; Bartzokis, T.; Yeoh, T.K.; Grogin, H.R.; Choi, D.; Schnittger, I. Enhanced detection of intracardiac sources of cerebral emboli by transesophageal echocardiography. Stroke, 1991, 22(6), 734-739.
[http://dx.doi.org/10.1161/01.STR.22.6.734] [PMID: 2057971]
[41]
Chenzbraun, A.; Pinto, F.J.; Schnittger, I. Biplane transesophageal echocardiography in the diagnosis of patent foramen ovale. J. Am. Soc. Echocardiogr., 1993, 6(4), 417-421.
[http://dx.doi.org/10.1016/S0894-7317(14)80240-X] [PMID: 8217208]
[42]
Mojadidi, M.K.; Roberts, S.C.; Winoker, J.S.; Romero, J.; Goodman-Meza, D.; Gevorgyan, R.; Tobis, J.M. Accuracy of transcranial Doppler for the diagnosis of intracardiac right-to-left shunt: a bivariate meta-analysis of prospective studies. JACC Cardiovasc. Imaging, 2014, 7(3), 236-250.
[http://dx.doi.org/10.1016/j.jcmg.2013.12.011] [PMID: 24560213]
[43]
Mojadidi, M.K.; Zhang, L.; Chugh, Y.; Eshtehardi, P.; Hovnanians, N.; Gevorgyan, R.; Mojaddedi, S.; Nezami, N.; Zaman, M.O.; Rafique, A.; Villablanca, P.A.; Tobis, J.M. Transcranial Doppler: Does addition of blood to agitated saline affect sensitivity for detecting cardiac right-to-left shunt? Echocardiography, 2016, 33(8), 1219-1227.
[http://dx.doi.org/10.1111/echo.13231] [PMID: 27095475]
[44]
Madala, D.; Zaroff, J.G.; Hourigan, L.; Foster, E. Harmonic imaging improves sensitivity at the expense of specificity in the detection of patent foramen ovale. Echocardiography, 2004, 21(1), 33-36.
[http://dx.doi.org/10.1111/j.0742-2822.2004.02168.x] [PMID: 14717718]
[45]
Mojadidi, M.K.; Winoker, J.S.; Roberts, S.C.; Msaouel, P.; Gevorgyan, R.; Zolty, R. Two-dimensional echocardiography using second harmonic imaging for the diagnosis of intracardiac right-to-left shunt: a meta-analysis of prospective studies. Int. J. Cardiovasc. Imaging, 2014, 30(5), 911-923.
[http://dx.doi.org/10.1007/s10554-014-0426-8] [PMID: 24740212]
[46]
Taniguchi, M.; Akagi, T.; Watanabe, N.; Okamoto, Y.; Nakagawa, K.; Kijima, Y.; Toh, N.; Ohtsuki, S.; Kusano, K.; Sano, S. Application of real-time three-dimensional transesophageal echocardiography using a matrix array probe for transcatheter closure of atrial septal defect. J. Am. Soc. Echocardiogr., 2009, 22(10), 1114-1120.
[http://dx.doi.org/10.1016/j.echo.2009.06.008] [PMID: 19647397]
[47]
Bartel, T.; Müller, S. Contemporary echocardiographic guiding tools for device closure of interatrial communications. Cardiovasc. Diagn. Ther., 2013, 3(1), 38-46.
[PMID: 24282743]
[48]
Belkin, R.N.; Pollack, B.D.; Ruggiero, M.L.; Alas, L.L.; Tatini, U. Comparison of transesophageal and transthoracic echocardiography with contrast and color flow Doppler in the detection of patent foramen ovale. Am. Heart J., 1994, 128(3), 520-525.
[http://dx.doi.org/10.1016/0002-8703(94)90626-2] [PMID: 8074014]
[49]
Sansoy, V. , et al. . Low yield of transthoracic echocardiography for cardiac source of embolism. Am. J. Cardiol., 1995, 75(2), pp. 166-169.
[http://dx.doi.org/10.1016/s0002-9149(00)80068-5] [PMID: 7810494]
[50]
Mas, J.L.; Arquizan, C.; Lamy, C.; Zuber, M.; Cabanes, L.; Derumeaux, G.; Coste, J. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N. Engl. J. Med., 2001, 345(24), 1740-1746.
[http://dx.doi.org/10.1056/NEJMoa011503] [PMID: 11742048]
[51]
Schuchlenz, H.W.; Weihs, W.; Horner, S.; Quehenberger, F. The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events. Am. J. Med., 2000, 109(6), 456-462.
[http://dx.doi.org/10.1016/S0002-9343(00)00530-1] [PMID: 11042234]
[52]
Gin, K.G.; Huckell, V.F.; Pollick, C. Femoral vein delivery of contrast medium enhances transthoracic echocardiographic detection of patent foramen ovale. J. Am. Coll. Cardiol., 1993, 22(7), 1994-2000.
[http://dx.doi.org/10.1016/0735-1097(93)90789-4] [PMID: 8245359]
[53]
Homma, S.; Sacco, R.L.; Di Tullio, M.R.; Sciacca, R.R.; Mohr, J.P. Atrial anatomy in non-cardioembolic stroke patients: Effect of medical therapy. J. Am. Coll. Cardiol., 2003, 42(6), 1066-1072.
[http://dx.doi.org/10.1016/S0735-1097(03)00907-0] [PMID: 13678932]
[54]
Bartel, T.; Müller, S. Device closure of interatrial communications: peri-interventional echocardiographic assessment. Eur. Heart J. Cardiovasc. Imaging, 2013, 14(7), 618-624.
[http://dx.doi.org/10.1093/ehjci/jet048] [PMID: 23598422]
[55]
Rigatelli, G.; Cardaioli, P.; Braggion, G.; Giordan, M.; Aggio, S.; Roncon, L. ICE-guided Patent Foramen Ovale (PFO) closure with lastest-generation devices: The ideal strategy for PFO-related migraine? J. Cardiovasc. Med. (Hagerstown), 2007, 8(8), 633-635.
[http://dx.doi.org/10.2459/01.JCM.0000281705.69230.ff] [PMID: 17667037]
[56]
Bartel, T.; Konorza, T.; Arjumand, J.; Ebradlidze, T.; Eggebrecht, H.; Caspari, G.; Neudorf, U.; Erbel, R. Intracardiac echocardiography is superior to conventional monitoring for guiding device closure of interatrial communications. Circulation, 2003, 107(6), 795-797.
[http://dx.doi.org/10.1161/01.CIR.0000057547.00909.1C] [PMID: 12591745]
[57]
Bartel, T.; Konorza, T.; Neudorf, U.; Ebralize, T.; Eggebrecht, H.; Gutersohn, A.; Erbel, R. Intracardiac echocardiography: An ideal guiding tool for device closure of interatrial communications. Eur. J. Echocardiogr., 2005, 6(2), 92-96.
[http://dx.doi.org/10.1016/j.euje.2004.07.007] [PMID: 15760685]
[58]
Cohnheim, J.; Cohnheim, J. Thrombose und embolie. Vorlesungen u ̈ berAllgemeine Pathologie, Hirschwald: Berlin . 1877. 1, p. 134.
[59]
Di Tullio, M.; Sacco, R.L.; Gopal, A.; Mohr, J.P.; Homma, S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann. Intern. Med., 1992, 117(6), 461-465.
[http://dx.doi.org/10.7326/0003-4819-117-6-461] [PMID: 1503349]
[60]
Foulkes, M.A.; Wolf, P.A.; Price, T.R.; Mohr, J.P.; Hier, D.B. The Stroke Data Bank: Design, methods, and baseline characteristics. Stroke, 1988, 19(5), 547-554.
[http://dx.doi.org/10.1161/01.STR.19.5.547] [PMID: 3363586]
[61]
Sacco, R.L.; Ellenberg, J.H.; Mohr, J.P.; Tatemichi, T.K.; Hier, D.B.; Price, T.R.; Wolf, P.A. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann. Neurol., 1989, 25(4), 382-390.
[http://dx.doi.org/10.1002/ana.410250410] [PMID: 2712533]
[62]
Adams, H.P., Jr; Bendixen, B.H.; Kappelle, L.J.; Biller, J.; Love, B.B.; Gordon, D.L.; Marsh, E.E., III Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 1993, 24(1), 35-41.
[http://dx.doi.org/10.1161/01.STR.24.1.35] [PMID: 7678184]
[63]
Cramer, S.C.; Rordorf, G.; Maki, J.H.; Kramer, L.A.; Grotta, J.C.; Burgin, W.S.; Hinchey, J.A.; Benesch, C.; Furie, K.L.; Lutsep, H.L.; Kelly, E.; Longstreth, W.T., Jr Increased pelvic vein thrombi in cryptogenic stroke: Results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) study. Stroke, 2004, 35(1), 46-50.
[http://dx.doi.org/10.1161/01.STR.0000106137.42649.AB] [PMID: 14657451]
[64]
Rigatelli, G.; Aggio, S.; Cardaioli, P.; Braggion, G.; Giordan, M.; Dell’avvocata, F.; Chinaglia, M.; Rigatelli, G.; Roncon, L.; Chen, J.P. Left atrial dysfunction in patients with patent foramen ovale and atrial septal aneurysm: An alternative concurrent mechanism for arterial embolism? JACC Cardiovasc. Interv., 2009, 2(7), 655-662.
[http://dx.doi.org/10.1016/j.jcin.2009.05.010] [PMID: 19628189]
[65]
Jain, A.; Cifu, A.S. Antithrombotic therapy for venous thromboembolic disease. JAMA, 2017, 317(19), 2008-2009.
[http://dx.doi.org/10.1001/jama.2017.1928] [PMID: 28510665]
[66]
Kent, D.M.; Ruthazer, R.; Weimar, C.; Mas, J.L.; Serena, J.; Homma, S.; Di Angelantonio, E.; Di Tullio, M.R.; Lutz, J.S.; Elkind, M.S.; Griffith, J.; Jaigobin, C.; Mattle, H.P.; Michel, P.; Mono, M.L.; Nedeltchev, K.; Papetti, F.; Thaler, D.E. An index to identify stroke-related vs. incidental patent foramen ovale in cryptogenic stroke. Neurology, 2013, 81(7), 619-625.
[http://dx.doi.org/10.1212/WNL.0b013e3182a08d59] [PMID: 23864310]
[67]
Hart, R.G.; Sharma, M.; Mundl, H.; Kasner, S.E.; Bangdiwala, S.I.; Berkowitz, S.D.; Swaminathan, B.; Lavados, P.; Wang, Y.; Wang, Y.; Davalos, A.; Shamalov, N.; Mikulik, R.; Cunha, L.; Lindgren, A.; Arauz, A.; Lang, W.; Czlonkowska, A.; Eckstein, J.; Gagliardi, R.J.; Amarenco, P.; Ameriso, S.F.; Tatlisumak, T.; Veltkamp, R.; Hankey, G.J.; Toni, D.; Bereczki, D.; Uchiyama, S.; Ntaios, G.; Yoon, B.W.; Brouns, R.; Endres, M.; Muir, K.W.; Bornstein, N.; Ozturk, S.; O’Donnell, M.J.; De Vries Basson, M.M.; Pare, G.; Pater, C.; Kirsch, B.; Sheridan, P.; Peters, G.; Weitz, J.I.; Peacock, W.F.; Shoamanesh, A.; Benavente, O.R.; Joyner, C.; Themeles, E.; Connolly, S.J.; Investigators, N.E. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N. Engl. J. Med., 2018, 378(23), 2191-2201.
[http://dx.doi.org/10.1056/NEJMoa1802686] [PMID: 29766772]
[68]
Kasner, S.E.; Swaminathan, B.; Lavados, P.; Sharma, M.; Muir, K.; Veltkamp, R.; Ameriso, S.F.; Endres, M.; Lutsep, H.; Messé, S.R.; Spence, J.D.; Nedeltechev, K.; Perera, K.; Santo, G.; Olavarria, V.; Lindgren, A.; Bangdiwala, S.; Shoamanesh, A.; Berkowitz, S.D.; Mundl, H.; Connolly, S.J.; Hart, R.G.; Investigators, N.E. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol., 2018, 17(12), 1053-1060.
[http://dx.doi.org/10.1016/S1474-4422(18)30319-3] [PMID: 30274772]
[69]
Anderson, F.A., Jr; Spencer, F.A. Risk factors for venous thromboembolism. Circulation, 2003, 107(23)(Suppl. 1), I9-I16.
[PMID: 12814980]
[70]
Kent, D.M.; Dahabreh, I.J.; Ruthazer, R.; Furlan, A.J.; Weimar, C.; Serena, J.; Meier, B.; Mattle, H.P.; Di Angelantonio, E.; Paciaroni, M.; Schuchlenz, H.; Homma, S.; Lutz, J.S.; Thaler, D.E. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: An individual participant data meta-analysis. Eur. Heart J., 2015, 36(35), 2381-2389.
[http://dx.doi.org/10.1093/eurheartj/ehv252] [PMID: 26141397]
[71]
Kernan, W.N.; Ovbiagele, B.; Black, H.R.; Bravata, D.M.; Chimowitz, M.I.; Ezekowitz, M.D.; Fang, M.C.; Fisher, M.; Furie, K.L.; Heck, D.V.; Johnston, S.C.; Kasner, S.E.; Kittner, S.J.; Mitchell, P.H.; Rich, M.W.; Richardson, D.; Schwamm, L.H.; Wilson, J.A. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2014, 45(7), 2160-2236.
[http://dx.doi.org/10.1161/STR.0000000000000024] [PMID: 24788967]
[72]
Patel, M.R.; Mahaffey, K.W.; Garg, J.; Pan, G.; Singer, D.E.; Hacke, W.; Breithardt, G.; Halperin, J.L.; Hankey, G.J.; Piccini, J.P.; Becker, R.C.; Nessel, C.C.; Paolini, J.F.; Berkowitz, S.D.; Fox, K.A.; Califf, R.M.; Investigators, R.A. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med., 2011, 365(10), 883-891.
[http://dx.doi.org/10.1056/NEJMoa1009638] [PMID: 21830957]
[73]
Granger, C.B.; Alexander, J.H.; McMurray, J.J.; Lopes, R.D.; Hylek, E.M.; Hanna, M.; Al-Khalidi, H.R.; Ansell, J.; Atar, D.; Avezum, A.; Bahit, M.C.; Diaz, R.; Easton, J.D.; Ezekowitz, J.A.; Flaker, G.; Garcia, D.; Geraldes, M.; Gersh, B.J.; Golitsyn, S.; Goto, S.; Hermosillo, A.G.; Hohnloser, S.H.; Horowitz, J.; Mohan, P.; Jansky, P.; Lewis, B.S.; Lopez-Sendon, J.L.; Pais, P.; Parkhomenko, A.; Verheugt, F.W.; Zhu, J.; Wallentin, L.; Committees, A. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2011, 365(11), 981-992.
[http://dx.doi.org/10.1056/NEJMoa1107039] [PMID: 21870978]
[74]
Giugliano, R.P.; Ruff, C.T.; Braunwald, E.; Murphy, S.A.; Wiviott, S.D.; Halperin, J.L.; Waldo, A.L.; Ezekowitz, M.D.; Weitz, J.I.; Špinar, J.; Ruzyllo, W.; Ruda, M.; Koretsune, Y.; Betcher, J.; Shi, M.; Grip, L.T.; Patel, S.P.; Patel, I.; Hanyok, J.J.; Mercuri, M.; Antman, E.M. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2013, 369(22), 2093-2104.
[http://dx.doi.org/10.1056/NEJMoa1310907] [PMID: 24251359]
[75]
Wallenborn, J.; Bertog, S.C.; Franke, J.; Steinberg, D.H.; Majunke, N.; Wilson, N.; Wunderlich, N.; Sievert, H. Recurrent events after percutaneous closure of patent foramen ovale. Catheter. Cardiovasc. Interv., 2013, 82(4), 541-546.
[http://dx.doi.org/10.1002/ccd.24511] [PMID: 22707325]
[76]
Meier, B.; Kalesan, B.; Mattle, H.P.; Khattab, A.A.; Hildick-Smith, D.; Dudek, D.; Andersen, G.; Ibrahim, R.; Schuler, G.; Walton, A.S.; Wahl, A.; Windecker, S.; Jüni, P.; Investigators, P.C.T. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N. Engl. J. Med., 2013, 368(12), 1083-1091.
[http://dx.doi.org/10.1056/NEJMoa1211716] [PMID: 23514285]
[77]
Khattab, A.A.M.B. The PC trial: An effective treatment not demonstrating effective power. Patent Foramen Ovale; Amin, Z.; Tobis, J.; Sievert, H; Carroll, J., Ed.; Springer: London, 2015.
[http://dx.doi.org/10.1007/978-1-4471-4987-3_24]
[78]
Carroll, J.D.; Saver, J.L.; Thaler, D.E.; Smalling, R.W.; Berry, S.; MacDonald, L.A.; Marks, D.S.; Tirschwell, D.L.; Investigators, R. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N. Engl. J. Med., 2013, 368(12), 1092-1100.
[http://dx.doi.org/10.1056/NEJMoa1301440] [PMID: 23514286]
[79]
Rengifo-Moreno, P.; Palacios, I.F.; Junpaparp, P.; Witzke, C.F.; Morris, D.L.; Romero-Corral, A. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: A systematic review and meta-analysis of randomized controlled trials. Eur. Heart J., 2013, 34(43), 3342-3352.
[http://dx.doi.org/10.1093/eurheartj/eht285] [PMID: 23847132]
[80]
Khan, A.R.; Bin Abdulhak, A.A.; Sheikh, M.A.; Khan, S.; Erwin, P.J.; Tleyjeh, I.; Khuder, S.; Eltahawy, E.A. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: A systematic review and meta-analysis. JACC Cardiovasc. Interv., 2013, 6(12), 1316-1323.
[http://dx.doi.org/10.1016/j.jcin.2013.08.001] [PMID: 24139929]
[81]
Kent, D.M.; Dahabreh, I.J.; Ruthazer, R.; Furlan, A.J.; Reisman, M.; Carroll, J.D.; Saver, J.L.; Smalling, R.W.; Jüni, P.; Mattle, H.P.; Meier, B.; Thaler, D.E. Device closure of patent foramen ovale after stroke: Pooled analysis of completed randomized trials. J. Am. Coll. Cardiol., 2016, 67(8), 907-917.
[http://dx.doi.org/10.1016/j.jacc.2015.12.023] [PMID: 26916479]
[82]
Hornung, M.; Bertog, S.C.; Franke, J.; Id, D.; Taaffe, M.; Wunderlich, N.; Vaskelyte, L.; Hofmann, I.; Sievert, H. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale. Eur. Heart J., 2013, 34(43), 3362-3369.
[http://dx.doi.org/10.1093/eurheartj/eht283] [PMID: 23842846]
[83]
Stortecky, S.; da Costa, B.R.; Mattle, H.P.; Carroll, J.; Hornung, M.; Sievert, H.; Trelle, S.; Windecker, S.; Meier, B.; Jüni, P. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: A network meta-analysis. Eur. Heart J., 2015, 36(2), 120-128.
[http://dx.doi.org/10.1093/eurheartj/ehu292] [PMID: 25112661]
[84]
Mojadidi, M.K.; Elgendy, A.Y.; Elgendy, I.Y.; Mahmoud, A.N.; Elbadawi, A.; Eshtehardi, P.; Patel, N.K.; Wayangankar, S.; Tobis, J.M.; Meier, B. Transcatheter Patent Foramen Ovale closure after cryptogenic stroke: An updated meta-analysis of randomized trials. JACC Cardiovasc. Interv., 2017, 10(21), 2228-2230.
[http://dx.doi.org/10.1016/j.jcin.2017.09.002] [PMID: 29122137]
[85]
Sitwala, P.; Khalid, M.F.; Khattak, F.; Bagai, J.; Bhogal, S.; Ladia, V.; Mukherjee, D.; Daggubati, R.; Paul, T.K. Percutaneous closure of patent foramen ovale in patients with cryptogenic stroke - An updated comprehensive meta-analysis. Cardiovasc. Revasc. Med., 2018. .
[PMID: 30282597]
[86]
Amplatzer PFO Occluder P120021. ; FDA website. October 28 , 2016..Available at: . https://www.accessdata.fda.gov/cdrh_docs/pdf12/p120021a.pdf
[87]
GORE® CARDIOFORM Septal Occluder - P050006/S060. . 2016..
[88]
Wein, T.; Lindsay, M.P.; Cote, R.; Foley, N.; Berlingieri, J.; Bhogal, S.; Bourgoin, A.; Buck, B.H.; Cox, J.; Davidson, D.; Dowlatshahi, D.; Douketis, J.; Falconer, J.; Field, T.; Gioia, L.; Gubitz, G.; Habert, J.; Jaspers, S.; Lum, C.; McNamara Morse, D.; Pageau, P.; Rafay, M.; Rodgerson, A.; Semchuk, B.; Sharma, M.; Shoamanesh, A.; Tamayo, A.; Smitko, E.; Gladstone, D.J. Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. Int. J. Stroke , 2018, 13(4), 420-443.
[89]
Pristipino, C.; Toni, D.; Violini, R. Regional consensus document on the indication to percutaneous closure of patent foramen ovale in the presence of cryptogenic stroke. G. Ital. Cardiol. Invasiva, 2010, 1, 21-31.
[90]
[IPG472], I. p. g., Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events., , 2013 December,
[91]
Powers, W.J.; Derdeyn, C.P.; Biller, J.; Coffey, C.S.; Hoh, B.L.; Jauch, E.C.; Johnston, K.C.; Johnston, S.C.; Khalessi, A.A.; Kidwell, C.S.; Meschia, J.F.; Ovbiagele, B.; Yavagal, D.R. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2015, 46(10), 3020-3035.
[http://dx.doi.org/10.1161/STR.0000000000000074] [PMID: 26123479]
[92]
Jauch, E.C.; Saver, J.L.; Adams, H.P., Jr; Bruno, A.; Connors, J.J.; Demaerschalk, B.M.; Khatri, P.; McMullan, P.W., Jr; Qureshi, A.I.; Rosenfield, K.; Scott, P.A.; Summers, D.R.; Wang, D.Z.; Wintermark, M.; Yonas, H. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2013, 44(3), 870-947.
[http://dx.doi.org/10.1161/STR.0b013e318284056a] [PMID: 23370205]
[93]
Marmagkiolis, K.; Hakeem, A.; Cilingiroglu, M.; Bailey, S.R.; Ruiz, C.; Hijazi, Z.M.; Herrmann, H.C.; Zajarias, A.; Goldberg, S.L.; Feldman, T. The Society for Cardiovascular Angiography and Interventions Structural Heart Disease Early Career Task Force survey results: Endorsed by the Society for Cardiovascular Angiography and Interventions. Catheter. Cardiovasc. Interv., 2012, 80(4), 706-711.
[http://dx.doi.org/10.1002/ccd.24535] [PMID: 22745016]
[94]
Horlick, E.; Kavinsky, C.J.; Amin, Z.; Boudoulas, K.D.; Carroll, J.D.; Hijazi, Z.M.; Leifer, D.; Lutsep, H.L.; Rhodes, J.F.; Tobis, J.M. SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke: The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Catheter. Cardiovasc. Interv., 2019, 93(5), 859-874.
[http://dx.doi.org/10.1002/ccd.28111] [PMID: 30896894]
[95]
Jux, C.; Bertram, H.; Wohlsein, P.; Bruegmann, M.; Paul, T. Interventional atrial septal defect closure using a totally bioresorbable occluder matrix: Development and preclinical evaluation of the BioSTAR device. J. Am. Coll. Cardiol., 2006, 48(1), 161-169.
[http://dx.doi.org/10.1016/j.jacc.2006.02.057] [PMID: 16814662]
[96]
Mullen, M.J.; Hildick-Smith, D.; De Giovanni, J.V.; Duke, C.; Hillis, W.S.; Morrison, W.L.; Jux, C. BioSTAR Evaluation STudy (BEST): a prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts. Circulation, 2006, 114(18), 1962-1967.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.664672] [PMID: 17062781]
[97]
Sigler, M.; Söderberg, B.; Schmitt, B.; Mellmann, A.; Bernhard, J. Carag Bioresorbable Septal Occluder (CBSO): Histopathology of experimental implants. EuroIntervention, 2018, 13(14), 1655-1661.
[http://dx.doi.org/10.4244/EIJ-D-17-00006] [PMID: 28555594]
[98]
Ntaios, G.; Papavasileiou, V.; Sagris, D.; Makaritsis, K.; Vemmos, K.; Steiner, T.; Michel, P. Closure of Patent Foramen Ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack: updated systematic review and meta-analysis. Stroke, 2018, 49(2), 412-418.
[http://dx.doi.org/10.1161/STROKEAHA.117.020030] [PMID: 29335335]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 2
Year: 2020
Published on: 14 October, 2020
Page: [135 - 150]
Pages: 16
DOI: 10.2174/1871525718666200203111641
Price: $65

Article Metrics

PDF: 42
HTML: 3